Zacks Investment Research
12 Nov 2026, 15:51 UTC · 34m ago
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Impact · against what's priced in
The USDA licensing of Cytopoint Plus provides a concrete catalyst to arrest market share loss in Zoetis's dermatology franchise by offering a market-leading 75-day treatment interval. This directly addresses the market's current refusal to price in a stabilization of the core companion animal portfolio.
- ZTS+0.40
Challenges what's priced in
- The price assumes
A stabilization of market share in the core dermatology and parasiticide franchises (Apoquel, Cytopoint, Simparica Trio)
The market is currently not paying for a stabilization of the dermatology franchise; however, the launch of a next-generation therapy with a 75-day relief interval—the longest among licensed mAbs—provides a structural advantage to protect and regain share.
What ZTS's price assumes · Aug 27
Search tags
